Combination drug therapy for advanced her2-positive tumors
Part of Cancer clinical trials.
This study tests a new drug (BM230) combined with a PD-1 inhibitor (a type of immunotherapy) for advanced cancers that have HER2. It aims to see if the combination is safe and effective in treating tumors that have stopped responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to give informed consent.
- Have a HER2-positive tumor (by test) or certain HER2 mutations (for lung cancer).
- Have advanced or metastatic cancer that progressed after at least one line of standard treatment (varies by tumor type).
- Have at least one measurable tumor (by imaging) and be willing to provide a tissue sample.
- Be in fairly good health: able to care for yourself, with adequate organ function (kidney, liver, heart, blood counts).
- Not have had prior treatment with anti-HER2 antibody drugs (except ADCs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BM230 for people with advanced solid tumors that have HER2 protein or gene changes. It aims to see if the drug is safe and effective for those who have run out of standard treatment options.
This trial tests a combination of two drugs: peginterferon α-2b (an immune-boosting drug) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). They hope the combo might work better for people with advanced solid tumors that haven't responded to other treatments.
This study tests a combination treatment for people with advanced solid tumors that have not responded to standard therapies. It uses a type of radiation therapy (PRaG) together with another treatment, and is specifically looking at people who have a low level of lymphocytes in their blood, which may affect how well the treatment works.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial is testing two new drugs (DB-1311 with BNT327 or DB-1305) in people with certain advanced or metastatic solid tumors that have not responded to prior treatments. It aims to see if the combination shrinks tumors or slows cancer growth.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.